Immunotherapies for Substance Use Disorders: State-of-the-Art Approaches
Saturday April 02, 2022
Eastern Time (ET)
University of Minnesota
Deaths attributed to synthetic opioids, such as fentanyl, and stimulants, such as cocaine and methamphetamine, have increased tremendously in the past year. Although several effective medications are available for treating opioid use disorder, relapse rates are high and medications for treating opioid overdose, such as naloxone, may be less effective against synthetic opioids compared to heroin. No medications have been approved in the U.S. for treating stimulant use disorders. Monoclonal antibodies and vaccines represent an alternative approach to treating overdose and substance use disorders. This symposium will provide an update on immunotherapies that are currently in clinical testing.
- University of Cincinnati
Pre-clinical and Clinical Development of a Humanized Anti-cocaine Monoclonal Antibody
Dr. Norman's presentation will focus on late-stage preclinical development milestones, and the use of the cocaine self-administration paradigm as an assay to predict clinical efficacy of the mAb. He may include Phase I safety data in human volunteers.
- Intervexion Therapeutics LLC
IXT-m200 for METH Use Disorder: Phase 2 Data and Approaches to Treatment with a METH Antibody
Dr. Stevens will describe the clinical pharmacology of IXT-m200, results from a recent Phase 2 study in non-treatment seeking METH users, and plans for pivotal clinical studies of treatment-seeking patients. A novel approach of combining IXT-m200 with existing cognitive therapies will be described.
- University of Minnesota
Development and Translation of Vaccines and Antibody-based Therapeutics for Opioid Use Disorders and Overdose
Dr. Pravetoni will discuss current pre-clinical and clinical studies focused on the development of vaccines and mAbs targeting heroin, oxycodone, fentanyl and its analogs. He will focus on novel pharmacological mechanisms and immunological biomarkers predictive of efficacy.